Carlos Martin has experience in mycobacterial genetics and molecular epidemiology of TB. He and his team aim to develop new TB vaccines and vaccination strategies to improve protection against pulmonary TB. Carlos Martin’s team designed and built MTBVAC, the first and only live attenuated vaccine against M. tuberculosis in clinical trials. He has published more than 180 publications cited more than 11,000 times.
He is Professor of Microbiology at the Faculty of Medicine of the University of Zaragoza, Spain and member of the TBVI Steering Committee. Dr. Martin’s research has been continually funded by National and European Research Programs in TB research. The Carlos Martin Team is part of CIBERES, a research network on respiratory diseases at the Spanish Instituto de Salud Carlos III (ISCIII). The research group is currently working on collaborative research projects on TB, together with research groups from Europe, Africa and America. It works to accelerate MTBVAC Phase 3 efficacy studies in collaboration with Biofabri, an industrial partner of the University of Zaragoza and with the support of the international organizations TBVI, IAVI and Bharat Biotech in India and Bio-Manguinhos/Fiocruz Brasil.